The knee hyaluronic acid injections market revenue totaled US$ 2.09 billion in 2023, according to the latest insights by Future Market Insights survey. The overall sales of knee hyaluronic acid injections are expected to reach US$ 3.40 billion, with growth at a CAGR of 5% by 2033.
With increasing awareness, the demand for various healthcare management programs and the availability of minimally invasive treatment options are rising. The increasing investment in technological advancements and novel product lines is expected to improve sales in the market at an accelerated pace.
How is the Adoption of Knee Hyaluronic Acid Injections Aiding Market Growth?
Rising health-related issues associated with obesity and aging, such as joint injury and knee osteoarthritis, have been of major concern. Knee osteoarthritis can bring immense pain to patients as they grow old and can result in causing further disability if left untreated. Thus, the need for increased medical care and improved healthcare services has also grown.
According to a study by NCBI, obesity is a major risk factor for osteoarthritis. It also revealed a prevalence of 22.9% of osteoarthritis in obesity surgery patients. Around 39.5 million United States adults were affected by osteoarthritis in 2019, as per Centers for Disease Control and Prevention (CDC) statistics.
The knee hyaluronic acid injection market plays a huge role as an alternative to knee arthroplasty surgery, which is expensive and has certain post-operation complications. The rapid development and commercialization of knee hyaluronic acid injections owing to the factors like superior efficacy, lesser side effects, and minimum patient discomfort give a great opportunity for this market, as the increasing number of osteoarthritic-affected patients are seeking a safe procedure that is affordable yet effective.
What are the Key Opportunities for Market Players?
As the number of osteoarthritic patients increases, so is the demand for solutions that can relieve the patients of the pain caused by the disease. Knee hyaluronic acid injection, also called viscosupplementation, is a successful procedure that helps improve the lubrication in synovial fluid. Thereby relieving pain and providing a comfortable activity level due to improved mobility.
FDA approvals for Knee hyaluronic acid injections and ongoing trials for new novel products in this segment are expected to provide great opportunities for the market players shortly.
Challenges in the Knee Hyaluronic Acid Injections Market?
Although viscosupplementations provide benefits such as greater efficacy and faster recovery timing, certain side effects are associated with these injections. These effects are usually mild and do not last for long durations and include temporary pain on the injection site, itching, redness, swelling, bruising around the joint, and fluid accumulation in the injected knee.
Stringent reimbursement policies in developed and emerging regions to consider Sodium Hyaluronic acid injections as a better treatment option, limitation of treatment cycle frequency, and funding provisions by organizations for the same can act as another challenge.
Despite claims and reasonable clinical evidence from manufacturers of efficacy and specific product advantages, many end-users remain doubtful that Knee Hyaluronic Acid Injections are an effective treatment for knee osteoarthritis. Therefore, the confidence of physicians and consultant doctors must be increased by providing them with detailed clinical studies and data that are specially designed to address these concerns.
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 5% |
| Market Valuation (2023) | US$ 2.09 billion |
| Market Valuation (2033) | US$ 3.40 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per Future Market Insights (FMI), the global market grew at a steady CAGR of 5% between 2018 and 2022. The market captured a valuation of US$ 1.64 billion
in 2018 and US$ 1.99 billion in 2022.
The knee hyaluronic acid injection market has seen incremental growth. It is expected to continue exhibiting a positive trajectory owing to an increasing preference for self-care and at-home healthcare practices for the aged population.
The availability of alternatives for high-cost knee osteoarthritis surgery with low-cost yet affordable options is driving current sales figures. Expansion and product launches in emerging markets are other key factors promoting market growth.
Commercializing highly superior and efficacious knee hyaluronic acid injections for knee osteoarthritis and the shifting trend of preferring single-injection-based knee hyaluronic acid injections over repeated injection regimes has shown a positive pattern.
Active engagement of companies in strategizing business opportunities through acquisitions and partnerships to strengthen their portfolio is likely to boost the market in the coming years.
Three-injection knee hyaluronic acid injections are leading the market at the global level and are estimated to gain nearly half of the market revenue share in the forecasted period. Major contributing factors include high affordability compared to the single-injection, while better efficacy and minimum side effects when compared to five-injection knee hyaluronic acid injections.
Ambulatory Surgical Centers is expected to be the most lucrative segment compared to the hospital segment in terms of market share and is expected to grow at a CAGR of over 5% through 2033.
The push towards price transparency enables patients to shop for low-cost, high-quality care; new technological innovations allow more orthopedic procedures to be conducted in the outpatient setting. Improving healthcare infrastructure is thus expected to boost the knee hyaluronic acid injection market in developed and emerging markets.
Principal Consultant
FMI Analysis reveals that North America dominated the revenue of the global knee hyaluronic acid injections market. In contrast, the United States market is expected to account for over 90% of the market share in 2023. It is further anticipated to grow at a CAGR of over 4% through 2033.
The dominance is driven by higher health awareness amongst the public and a focus on enhancing healthcare services by healthcare providers. Due to the rise in outpatient healthcare services models with a minimum cost of treatment and the nature of Knee Hyaluronic Acid Injections treatment patterns for Knee Osteoarthritis, Ambulatory surgical centers are the most lucrative segment in this region.
Germany is expected to account for over 19% of the Europe market in 2023, followed by the United Kingdom, with over 16% of the market share.
According to the Journal of Health Monitoring- 2017, individuals aged 65 and over accounted for osteoarthritis, including nearly half of all women and one-third of men. The prevalence of osteoarthritis is expected to increase further owing to the population aging in Germany.
Knee Hyaluronic acid injection treatment, thus, has huge potential in this region. It provides a rewarding opportunity to the players serving in this market during the forecast period.
The market for knee hyaluronic acid injections in East Asia is estimated to exhibit a 5.2% CAGR during the forecast period, with Japan dominating this region. Japan is expected to account for over 48% of the East Asia market share in revenue in 2023.
Reimbursement coverage policy for knee hyaluronic acid injections and provisions for uniform and affordable healthcare benefits packages and programs are expected to drive the market in the future.
Additionally, players are entering into new product launches and manufacturing and marketing collaborations as strategies to expand their service offerings, which is likely to augment market growth in Japan.
Manufacturers of knee hyaluronic acid injections aim to carry out strategic expansions through mergers and acquisitions, Product Out- Licensing, and exclusive distribution to consolidate growth in a competitive market.
The market is highly competitive by the present key players globally. These players are developing unique and innovative products to attract consumers' requirements. These players focus on consumers' desires and offer improved products.
The key players are adopting strategies to upsurge the global market are mergers, acquisitions, partnerships, collaborations, and product launches. They continue to fuel the global market through their innovations and invest huge amounts in research and development activities. These players are reaching more audiences by attending seminars, exhibitions, and trade shows.
Other Essential Players in the Global Market are:
Recent Developments in the Global Market are:
In May 2021, Ono and Seikagaku announced a manufacturing and marketing approval in Japan for JOYCLU® 30mg intra-articular injection, a joint function improvement agent, for the indication of osteoarthritis (Knee Joint and Hip Joint).
Seikagaku also entered into exclusive marketing and distribution agreements in all commercialized markets with leading players such as Zimmer Biomet (U.S.), MDM S.p.A. (Italy), Kaken Pharmaceutical Co. (Japan), and Kunming Baker Norton Pharmaceutical Co. Ltd. (China).
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | United States, United Kingdom, Japan, India, China, Australia, Germany |
| Key Segments Covered | Product Type, End User, Region |
| Key Companies Profiled | Sanofi; Anika Therapeutics Inc. (DePuy Synthes Inc.); Seikagaku Corporation; Zimmer Biomet; Institut Biochimique SA (Bioventus LLC); Fidia Farmaceutici S.p.A; Meiji Seika Pharma Co. Ltd. (OrthogenRx); Ferring B.V.; Viatrus Inc.; Hanmi Pharm Co. Ltd. (Teva Pharmaceuticals Industries Ltd.); Chugai Pharmaceuticals Co. Ltd.; Haohai Biological Technology; Hunan Jingfeng Pharmaceutical Co. Ltd.; SciViscion Biotech Inc. (MACO PHARMA S.A.S); BioPolymer GmbH & Co. KG; TRB Chemedica International SA; MDT Int’l S. A. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is estimated to be about US$ 2.09 billion in 2023.
Demand for solutions that can relieve the patients of the pain caused by the disease is increasing with the number of osteoarthritic patients.
The market advanced at a CAGR of 5% between 2018 and 2022.
The United States market is expected to account for over 90% of the market share in 2023.
Seikagaku Corporation, Zimmer Biomet, and Institut Biochimique SA (Bioventus LLC) are some key players in the market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Product, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Product, 2023 to 2033
5.3.1. Single Injection Knee Hyaluronic Acid Injections
5.3.2. Three Injection Knee Hyaluronic Acid Injections
5.3.3. Five Injection Knee Hyaluronic Acid Injections
5.3.4. Next Generation (Steroid Combination)
5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centers
6.3.3. Ambulatory Surgical Centers
6.3.4. Retail Pharmacies
6.3.5. Online Sales
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Product
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Product
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product
9.3.3. By End User
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Product
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product
10.3.3. By End User
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Product
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product
11.3.3. By End User
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Product
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product
12.3.3. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product
13.2.3. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product
13.3.3. By End User
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Product
14.2.3. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product
14.3.3. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Product
15.1.2.2. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Product
15.2.2.2. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Product
15.3.2.2. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Product
15.4.2.2. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Product
15.5.2.2. By End User
15.6. U.K.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Product
15.6.2.2. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Product
15.7.2.2. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Product
15.8.2.2. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Product
15.9.2.2. By End User
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Product
15.10.2.2. By End User
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Product
15.11.2.2. By End User
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Product
15.12.2.2. By End User
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Product
15.13.2.2. By End User
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Product
15.14.2.2. By End User
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Product
15.15.2.2. By End User
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Product
15.16.2.2. By End User
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Product
15.17.2.2. By End User
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Product
15.18.2.2. By End User
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Product
15.19.2.2. By End User
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Product
15.20.2.2. By End User
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Product
15.21.2.2. By End User
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Product
15.22.2.2. By End User
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Product
15.23.2.2. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product
16.3.3. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Sanofi
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Anika Therapeutics Inc. (DePuy Synthes Inc.)
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Seikagaku Corporation
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Zimmer Biomet
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Institut Biochimique SA (Bioventus LLC)
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Fidia Farmaceutici S.p.A
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Meiji Seika Pharma Co. Ltd. (OrthogenRx)
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Ferring B.V.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Viatrus Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Hanmi Pharm Co. Ltd. (Teva Pharmaceuticals Industries ltd.)
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Chugai Pharmaceuticals Co. Ltd.
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
17.1.12. Haohai Biological Technology
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.12.5.2. Product Strategy
17.1.12.5.3. Channel Strategy
17.1.13. Hunan Jingfeng Pharmaceutical Co. Ltd.
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.13.5.2. Product Strategy
17.1.13.5.3. Channel Strategy
17.1.14. SciViscion Biotech Inc. (MACO PHARMA S.A.S)
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
17.1.14.5.2. Product Strategy
17.1.14.5.3. Channel Strategy
17.1.15. BioPolymer GmbH & Co. KG
17.1.15.1. Overview
17.1.15.2. Product Portfolio
17.1.15.3. Profitability by Market Segments
17.1.15.4. Sales Footprint
17.1.15.5. Strategy Overview
17.1.15.5.1. Marketing Strategy
17.1.15.5.2. Product Strategy
17.1.15.5.3. Channel Strategy
17.1.16. TRB Chemedica International SA
17.1.16.1. Overview
17.1.16.2. Product Portfolio
17.1.16.3. Profitability by Market Segments
17.1.16.4. Sales Footprint
17.1.16.5. Strategy Overview
17.1.16.5.1. Marketing Strategy
17.1.16.5.2. Product Strategy
17.1.16.5.3. Channel Strategy
17.1.17. MDT Int’l S. A.
17.1.17.1. Overview
17.1.17.2. Product Portfolio
17.1.17.3. Profitability by Market Segments
17.1.17.4. Sales Footprint
17.1.17.5. Strategy Overview
17.1.17.5.1. Marketing Strategy
17.1.17.5.2. Product Strategy
17.1.17.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Knee Hyaluronic Acid Injections Market
